{"id":831,"date":"2021-02-16T06:04:08","date_gmt":"2021-02-16T06:04:08","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=831"},"modified":"2021-02-16T06:04:08","modified_gmt":"2021-02-16T06:04:08","slug":"07-feb-2021-bevacizumab-shows-clinical-efficacy-by-improving-oxygenation","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/07-feb-2021-bevacizumab-shows-clinical-efficacy-by-improving-oxygenation\/","title":{"rendered":"(07 Feb 2021) Bevacizumab- shows clinical efficacy by improving oxygenation"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Efficacy and tolerability of bevacizumab in patients with severe Covid-19<\/p>\n<p>https:\/\/doi.org\/10.1038\/s41467-021-21085-8<\/p>\n<p class=\"\">NCT04275414-From Feb 15 to April 5, 2020, we conducted a single-arm trial (NCT04275414) and recruited 26 patients from 2-centers (China and Italy) with severe Covid-19, with respiratory rate &gt;\/=30 times\/min, oxygen saturation &lt;\/=93% with ambient air, or partial arterial oxygen pressure to fraction of inspiration O2 ratio (PaO2\/FiO2) &gt;100 mmHg and &lt;\/=300 mmHg, and diffuse pneumonia confirmed by chest imaging. Followed up for 28 days. Among these, bevacizumab plus standard care markedly improves the PaO2\/FiO2 ratios at days 1 and 7. By day 28, 24 (92%) patients show improvement in oxygen-support status, 17 (65%) patients are discharged, and none show worsen oxygen-support status nor die. Significant reduction of lesion areas\/ratios are shown in chest computed tomography (CT) or X-ray within 7 days. Of 14 patients with fever, body temperature normalizes within 72 h in 13 (93%) patients. Relative to comparable controls, bevacizumab shows clinical efficacy by improving oxygenation and shortening oxygen-support duration. Our findings suggest bevacizumab plus standard care is highly beneficial for patients with severe Covid-19.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Efficacy and tolerability of bevacizumab in patients with severe Covid-19 https:\/\/doi.org\/10.1038\/s41467-021-21085-8 NCT04275414-From Feb 15 to April 5, 2020, we conducted a single-arm trial (NCT04275414) and recruited 26 patients from 2-centers (China and Italy) with severe Covid-19, with respiratory rate &gt;\/=30&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/07-feb-2021-bevacizumab-shows-clinical-efficacy-by-improving-oxygenation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(07 Feb 2021) Bevacizumab- shows clinical efficacy by improving oxygenation&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[104,6,4],"tags":[105],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/831"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=831"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/831\/revisions"}],"predecessor-version":[{"id":832,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/831\/revisions\/832"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}